scholarly journals A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

2016 ◽  
Vol 215 (1) ◽  
pp. 24-33 ◽  
Author(s):  
Joanne M. Langley ◽  
Naresh Aggarwal ◽  
Azhar Toma ◽  
Scott A. Halperin ◽  
Shelly A. McNeil ◽  
...  
Vaccine ◽  
2019 ◽  
Vol 37 (30) ◽  
pp. 4031-4039 ◽  
Author(s):  
Abenaya Muralidharan ◽  
Marsha S. Russell ◽  
Louise Larocque ◽  
Caroline Gravel ◽  
Simon Sauvé ◽  
...  

2016 ◽  
Vol 23 (3) ◽  
pp. 186-188 ◽  
Author(s):  
Kathleen M. Neuzil

ABSTRACTIn accompanying papers (P. L. Acosta, M. T. Caballero, and F. P. Polack, Clin Vaccine Immunol 23:189–195, 2016,http://dx.doi.org/10.1128/CVI.00609-15; M. Vissers, I. M. L. Ahout, M. I. de Jonge, and G. Ferwerda, Clin Vaccine Immunol 23:243–245, 2016,http://dx.doi.org/10.1128/CVI.00590-15) in this issue ofClinical and Vaccine Immunology, the history of and immune mechanisms underlying vaccine-enhanced respiratory syncytial virus (RSV) disease and of investigations of mucosal antibodies and their association with viral load in RSV-infected children, respectively, are described. This commentary discusses RSV vaccine candidates, target populations, and the challenges associated with achieving a safe and effective vaccine.


2015 ◽  
Vol 54 (48) ◽  
pp. 14531-14534 ◽  
Author(s):  
Xiaozhou Luo ◽  
Tao Liu ◽  
Ying Wang ◽  
Haiqun Jia ◽  
Yuhan Zhang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document